AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34289977 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced Expired Volume in 1 second (FEV)
Number of subjects: 237
Study 34290067 — intervention group
Group type: EXPERIMENTAL
Intervention: Awake mapping
Number of subjects: 0
Study 34290067 — intervention group
Group type: EXPERIMENTAL
Intervention: Asleep mapping
Number of subjects: 0
Study 34290067 — intervention group
Group type: COMPARATOR
Intervention: No mapping
Number of subjects: 0
Study 34290403 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Number of subjects: 0
Study 34291073 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence to a healthy lifestyle
Number of subjects: 0
Study 34291073 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 34291312 — intervention group
Group type: EXPERIMENTAL
Intervention: Children diagnosed before 6 years of age
Number of subjects: 8502
Study 34291312 — intervention group
Group type: COMPARATOR
Intervention: Children diagnosed at 6-13 years of age
Number of subjects: 8502
Study 34291312 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial seroconversion before 2 years of age
Number of subjects: 8502
Study 34291312 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial seroconversion after 2 years of age
Number of subjects: 8502
Study 34291312 — intervention group
Group type: EXPERIMENTAL
Intervention: Minor alleles of rs1004446 (INS)
Number of subjects: 8502
Study 34291312 — intervention group
Group type: EXPERIMENTAL
Intervention: Minor alleles of rs2476601 (PTPN22)
Number of subjects: 8502
Study 34291312 — intervention group
Group type: EXPERIMENTAL
Intervention: Minor alleles of rs428595 (PPIL2)
Number of subjects: 8502
Study 34291312 — intervention group
Group type: EXPERIMENTAL
Intervention: Minor alleles of rs113306148 (PLEKHA1)
Number of subjects: 8502
Study 34291312 — intervention group
Group type: EXPERIMENTAL
Intervention: Minor alleles of rs73043122 (RNASET2)
Number of subjects: 8502
Study 34291470 — intervention group
Group type: EXPERIMENTAL
Intervention: Adhesive composite restorations
Number of subjects: 87
Study 34291703 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon dioxide (CO2) laser treatment, 3 sessions over 20 weeks
Number of subjects: 14
Study 34291703 — intervention group
Group type: EXPERIMENTAL
Intervention: Histological analysis after CO2 laser treatment
Number of subjects: 14
Study 34291703 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunohistochemical analysis after CO2 laser treatment
Number of subjects: 14
Study 34291810 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients admitted during the third pandemic wave
Number of subjects: 1829
Study 34291810 — intervention group
Group type: COMPARATOR
Intervention: Patients admitted before February 1, 2021
Number of subjects: 1829
Study 34291813 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic corticosteroids plus intranasal steroid/mucolytic/decongestant
Number of subjects: 18
Study 34291813 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 18
Study 34291850 — intervention group
Group type: EXPERIMENTAL
Intervention: preAD
Number of subjects: 62
Study 34291850 — intervention group
Group type: EXPERIMENTAL
Intervention: CIs
Number of subjects: 62
Study 34291850 — intervention group
Group type: COMPARATOR
Intervention: NCs
Number of subjects: 62
Study 34291990 — intervention group
Group type: EXPERIMENTAL
Intervention: Hamilton Anxiety Inventory (HAM-A)
Number of subjects: 0
Study 34292174 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective RET-inhibitors (selpercatinib and pralsetinib)
Number of subjects: 0
Study 34292174 — intervention group
Group type: EXPERIMENTAL
Intervention: Mutational analysis combined with cytological assessment
Number of subjects: 0
Study 34292174 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigation of immune-based therapy
Number of subjects: 0
Study 34292185 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor necrosis factor-α
Number of subjects: 0
Study 34292185 — intervention group
Group type: EXPERIMENTAL
Intervention: TGF-β1
Number of subjects: 0
Study 34292185 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein
Number of subjects: 0
Study 34292185 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-existing pain condition (yes)
Number of subjects: 0
Study 34292185 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritraumatic life stress (higher levels)
Number of subjects: 0
Study 34292214 — intervention group
Group type: EXPERIMENTAL
Intervention: First dose of CoronaVac vaccine
Number of subjects: 0
Study 34292324 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthracycline-based regimens
Number of subjects: 282
Study 34292324 — intervention group
Group type: EXPERIMENTAL
Intervention: Consolidative autologous stem cell transplant (ASCT) in first complete remission (CR1)
Number of subjects: 282
Study 34292324 — intervention group
Group type: EXPERIMENTAL
Intervention: Age ≥60 years, ECOG performance status >2, elevated C-reactive protein, elevated β2 microglobulin
Number of subjects: 282
Study 34292324 — intervention group
Group type: EXPERIMENTAL
Intervention: AITL score (novel prognostic score)
Number of subjects: 282
Study 34292324 — intervention group
Group type: EXPERIMENTAL
Intervention: POD24 (progression of disease within 24 months)
Number of subjects: 282
Study 34292473 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic tonsillitis group
Number of subjects: 46
Study 34292473 — intervention group
Group type: COMPARATOR
Intervention: Tonsillar hypertrophy group
Number of subjects: 46
Study 34292516 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol sedation (0.03 mg/kg)
Number of subjects: 80
Study 34292537 — intervention group
Group type: EXPERIMENTAL
Intervention: Ba-Duan-Jin (BDJ) exercise and placebo capsule
Number of subjects: 104
Study 34292537 — intervention group
Group type: COMPARATOR
Intervention: Pregabalin capsule and wellness education with guided muscle-relaxation exercises
Number of subjects: 104
Study 34292891 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective refraction (SR)
Number of subjects: 90
Study 34292891 — intervention group
Group type: EXPERIMENTAL
Intervention: Autorefraction (AR)
Number of subjects: 90
Study 34292891 — intervention group
Group type: EXPERIMENTAL
Intervention: Wavefront aberrometry (WA)
Number of subjects: 90
Study 34292891 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial least squares regression and random forest regression
Number of subjects: 90
Study 34292891 — intervention group
Group type: EXPERIMENTAL
Intervention: Astigmatic vectors
Number of subjects: 90
Study 34293119 — intervention group
Group type: EXPERIMENTAL
Intervention: Convalescent plasma with high neutralizing antibody titers
Number of subjects: 25
Study 34293201 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiation therapy with concurrent doxorubicin (CC-IMRT)
Number of subjects: 27
Study 34293201 — intervention group
Group type: COMPARATOR
Intervention: Intensity-modulated radiation therapy alone (IMRT)
Number of subjects: 27
Study 34293369 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous closure
Number of subjects: 201
Study 34293369 — intervention group
Group type: EXPERIMENTAL
Intervention: Assisted closure
Number of subjects: 201
Study 34293369 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 201
Study 34293527 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose L-theanine
Number of subjects: 0
Study 34293726 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic pulmonary perfusion images from 4DCT using deep learning
Number of subjects: 0
Study 34293802 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanreotide autogel
Number of subjects: 80
Study 34294152 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen scaffold/umbilical cord mesenchymal stem cells (CS/UC-MSCs)
Number of subjects: 18
Study 34294637 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive keratograph break-up time (NIKBUT)
Number of subjects: 288
Study 34294637 — intervention group
Group type: EXPERIMENTAL
Intervention: Tear break-up time (TBUT)
Number of subjects: 288
Study 34294637 — intervention group
Group type: EXPERIMENTAL
Intervention: Schirmer test
Number of subjects: 288
Study 34294637 — intervention group
Group type: EXPERIMENTAL
Intervention: Tear meniscus height (TMH)
Number of subjects: 288
Study 34294637 — intervention group
Group type: EXPERIMENTAL
Intervention: Bulbar redness (BR)
Number of subjects: 288
Study 34294637 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocular Surface Disease Index (OSDI) scores
Number of subjects: 288
Study 34294862 — intervention group
Group type: EXPERIMENTAL
Intervention: SYNB1618 (engineered bacterial therapeutic)
Number of subjects: 0
Study 34295186 — intervention group
Group type: EXPERIMENTAL
Intervention: Naldemedine 0.2 mg
Number of subjects: 2336
Study 34295186 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2336
Study 34295813 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy with intensity-modulated radiation therapy (IMRT) at a total dose of 40 Gy in 20 fractions.
Number of subjects: 70
Study 34296150 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS (2 mA for 20 min per session, 10 sessions total)
Number of subjects: 31
Study 34296150 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 31
Study 34296321 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal vitamin B supplementation
Number of subjects: 4746
Study 34296417 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxidectin 8 mg fixed-dose
Number of subjects: 96
Study 34296417 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxidectin weight-based dosing
Number of subjects: 96
Study 34296427 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic corticosteroids
Number of subjects: 0
Study 34296427 — intervention group
Group type: EXPERIMENTAL
Intervention: Earlier corticosteroid and tocilizumab intervention
Number of subjects: 0
Study 34296522 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-weekly subcutaneous semaglutide for weight management
Number of subjects: 0
Study 34296522 — intervention group
Group type: EXPERIMENTAL
Intervention: IWQOL-Lite-CT composites
Number of subjects: 0
Study 34296674 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-pharmaceutical interventions (NPI)
Number of subjects: 0
Study 34296962 — intervention group
Group type: EXPERIMENTAL
Intervention: β-TI patients
Number of subjects: 45
Study 34296962 — intervention group
Group type: EXPERIMENTAL
Intervention: Hs-CRP
Number of subjects: 45
Study 34296962 — intervention group
Group type: COMPARATOR
Intervention: Healthy individuals
Number of subjects: 45
Study 34297046 — intervention group
Group type: EXPERIMENTAL
Intervention: Azacitidine (75 mg/m2) administered IV once daily on days 1 to 7 of a 28-day cycle
Number of subjects: 18
Study 34297062 — intervention group
Group type: EXPERIMENTAL
Intervention: Malaria in pregnancy (MiP) at least once
Number of subjects: 493
Study 34297062 — intervention group
Group type: EXPERIMENTAL
Intervention: Placental malaria diagnosed by qPCR
Number of subjects: 493
Study 34297062 — intervention group
Group type: EXPERIMENTAL
Intervention: High parasite density at delivery
Number of subjects: 493
Study 34297062 — intervention group
Group type: EXPERIMENTAL
Intervention: Malaria at second antenatal care visit
Number of subjects: 493
Study 34297062 — intervention group
Group type: EXPERIMENTAL
Intervention: High parasite density at second antenatal care visit
Number of subjects: 493
Study 34297159 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Number of subjects: 0
Study 34297159 — intervention group
Group type: EXPERIMENTAL
Intervention: CAP-100
Number of subjects: 0
Study 34297259 — intervention group
Group type: EXPERIMENTAL
Intervention: Online training system with a 32-exercise training course providing online instruction (about 15 min/week) in 13 core family therapy techniques.
Number of subjects: 48
Study 34297797 — intervention group
Group type: EXPERIMENTAL
Intervention: Administration of IGF-1 to old mice
Number of subjects: 0
Study 34297797 — intervention group
Group type: EXPERIMENTAL
Intervention: Administration of anti-TNF-α antibodies to human patients
Number of subjects: 0
Study 34297797 — intervention group
Group type: COMPARATOR
Intervention: Peripheral B cells producing TNF-α
Number of subjects: 0
Study 34297969 — intervention group
Group type: EXPERIMENTAL
Intervention: Midurethral sling operation
Number of subjects: 100
Study 34298149 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypophosphatemic patients with acute liver failure (ALF)
Number of subjects: 76
Study 34298149 — intervention group
Group type: COMPARATOR
Intervention: Normophosphatemic patients with acute liver failure (ALF)
Number of subjects: 76
Study 34298376 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommended treatments (R-T) for first-line (1L) patients
Number of subjects: 1500
Study 34298376 — intervention group
Group type: COMPARATOR
Intervention: Non-recommended treatments (NR-T) for first-line (1L) patients
Number of subjects: 1500
Study 34298376 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommended treatments (R-T) for pre-treated (2L+) patients
Number of subjects: 1500
Study 34298376 — intervention group
Group type: COMPARATOR
Intervention: Non-recommended treatments (NR-T) for pre-treated (2L+) patients
Number of subjects: 1500
Study 34298554 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab
Number of subjects: 1709
Study 34298589 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 2080
Study 34298589 — intervention group
Group type: COMPARATOR
Intervention: Ticlopidine
Number of subjects: 2080
Study 34298589 — intervention group
Group type: COMPARATOR
Intervention: Fish oil
Number of subjects: 2080
Study 34298589 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 2080
Study 34298589 — intervention group
Group type: COMPARATOR
Intervention: Dipyridamole
Number of subjects: 2080
Study 34298589 — intervention group
Group type: COMPARATOR
Intervention: Dipyridamole plus aspirin
Number of subjects: 2080
Study 34298589 — intervention group
Group type: COMPARATOR
Intervention: Low-intensity warfarin
Number of subjects: 2080
Study 34298589 — intervention group
Group type: COMPARATOR
Intervention: Sulphinpyrazone
Number of subjects: 2080
Study 34298589 — intervention group
Group type: COMPARATOR
Intervention: GTN patch
Number of subjects: 2080
Study 34298717 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted methylation cell-free DNA (cfDNA)-based multi-cancer early detection (MCED) test
Number of subjects: 6200
Study 34300020 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational videos on Pediatric Obesity Management using the five As (Ask, Assess, Advise, Agree, Assist)
Number of subjects: 0
Study 34300133 — intervention group
Group type: EXPERIMENTAL
Intervention: Home smoking ban
Number of subjects: 202
Study 34300133 — intervention group
Group type: COMPARATOR
Intervention: Inconsistent home smoking ban
Number of subjects: 202
Study 34300133 — intervention group
Group type: COMPARATOR
Intervention: No home smoking ban
Number of subjects: 202
Study 34300217 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal urinalysis
Number of subjects: 145
Study 34300217 — intervention group
Group type: COMPARATOR
Intervention: Normal urinalysis
Number of subjects: 145
Study 34300338 — intervention group
Group type: EXPERIMENTAL
Intervention: PiCCO cannula for three days
Number of subjects: 23
Study 34300338 — intervention group
Group type: COMPARATOR
Intervention: PiCCO cannula for five days
Number of subjects: 23
Study 34300402 — intervention group
Group type: EXPERIMENTAL
Intervention: BLE beacon-based algorithm for remote measurement of social behavior
Number of subjects: 0
Study 34300402 — intervention group
Group type: EXPERIMENTAL
Intervention: BLE beacon sensors setup by participants/caregivers
Number of subjects: 0
Study 34301173 — intervention group
Group type: EXPERIMENTAL
Intervention: Erenumab 70 mg
Number of subjects: 1622
Study 34301173 — intervention group
Group type: EXPERIMENTAL
Intervention: Erenumab 140 mg
Number of subjects: 1622
Study 34301173 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1622
Study 34301173 — intervention group
Group type: EXPERIMENTAL
Intervention: Erenumab
Number of subjects: 1622
Study 34301221 — intervention group
Group type: EXPERIMENTAL
Intervention: CXD101
Number of subjects: 51
Study 34301237 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental caries data registered at an examination
Number of subjects: 170
Study 34301237 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental caries data from patient dental record
Number of subjects: 170
Study 34301237 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental caries data from SKaPa registry
Number of subjects: 170
Study 34301237 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraclass correlation coefficient (ICC) between researcher and patient journal
Number of subjects: 170
Study 34301237 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraclass correlation coefficient (ICC) between patient dental record and SKaPa
Number of subjects: 170
Study 34301237 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraclass correlation coefficient (ICC) between researcher and SKaPa
Number of subjects: 170
Study 34301237 — intervention group
Group type: EXPERIMENTAL
Intervention: SKaPa registry information
Number of subjects: 170
Study 34301246 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable device capable of detecting and reversing overdose
Number of subjects: 97
Study 34301273 — intervention group
Group type: EXPERIMENTAL
Intervention: High HEI tertile
Number of subjects: 365
Study 34301273 — intervention group
Group type: COMPARATOR
Intervention: Low HEI tertile
Number of subjects: 365
Study 34301808 — intervention group
Group type: EXPERIMENTAL
Intervention: Pacmilimab 10 mg/kg + Ipilimumab 3 mg/kg administered every 3 weeks
Number of subjects: 27
Study 34301809 — intervention group
Group type: EXPERIMENTAL
Intervention: Pacmilimab at a recommended phase 2 dose (RP2D) of 10 mg/kg administered intravenously every 14 days
Number of subjects: 114
Study 34301809 — intervention group
Group type: EXPERIMENTAL
Intervention: Pacmilimab at RP2D of 10 mg/kg
Number of subjects: 114
Study 34301810 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab 10 mg/kg intravenously every 2 weeks
Number of subjects: 116
Study 34302257 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediastinal shift angle (MSA)
Number of subjects: 0
Study 34302290 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime 40 mg/kg IV q6h (max 8 g/day)
Number of subjects: 29
Study 34302517 — intervention group
Group type: EXPERIMENTAL
Intervention: Management of arterial partial pressure of carbon dioxide (PaCO2)
Number of subjects: 1100
Study 34302533 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib-pioglitazone regimen
Number of subjects: 10
Study 34302533 — intervention group
Group type: COMPARATOR
Intervention: Imatinib monotherapy
Number of subjects: 10
Study 34302589 — intervention group
Group type: EXPERIMENTAL
Intervention: Eribulin 1.4 mg/m² in combination with trastuzumab and pertuzumab (HP)
Number of subjects: 0
Study 34302589 — intervention group
Group type: EXPERIMENTAL
Intervention: Eribulin 1.4 mg/m²
Number of subjects: 0
Study 34302589 — intervention group
Group type: EXPERIMENTAL
Intervention: Genomic alterations
Number of subjects: 0
Study 34302711 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 34302748 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient powders
Number of subjects: 0
Study 34302748 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 34302760 — intervention group
Group type: EXPERIMENTAL
Intervention: Bictegravir, emtricitabine, and tenofovir alafenamide (single-tablet regimen)
Number of subjects: 102
Study 34302788 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyomavirus-specific T cells infusion
Number of subjects: 12
Study 34302856 — intervention group
Group type: EXPERIMENTAL
Intervention: zWFL
Number of subjects: 464
Study 34302856 — intervention group
Group type: EXPERIMENTAL
Intervention: zBMI
Number of subjects: 464
Study 34302856 — intervention group
Group type: EXPERIMENTAL
Intervention: zWFL and zBMI
Number of subjects: 464
Study 34303017 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 1314
Study 34303017 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1314
Study 34303860 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics
Number of subjects: 0
Study 34303860 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 34304148 — intervention group
Group type: EXPERIMENTAL
Intervention: Nexus Narcolepsy Registry participants
Number of subjects: 1024
Study 34304148 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric symptom onset
Number of subjects: 1024
Study 34304148 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall mean time from symptom onset to diagnosis
Number of subjects: 1024
Study 34304385 — intervention group
Group type: EXPERIMENTAL
Intervention: IDegAsp
Number of subjects: 236
Study 34304968 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg/day for up to 3 years, in addition to ongoing corticosteroid treatment.
Number of subjects: 13
Study 34304968 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen treatment.
Number of subjects: 13
Study 34304968 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroids only (historical control).
Number of subjects: 13
Study 34305401 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher TyG Index (tertiles)
Number of subjects: 1432
Study 34305452 — intervention group
Group type: EXPERIMENTAL
Intervention: CT genotype of CD14 SNP rs2569190
Number of subjects: 1002
Study 34305452 — intervention group
Group type: COMPARATOR
Intervention: All investigated genetic variants
Number of subjects: 1002
Study 34305947 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunopeptidome-guided peptide warehouse design for CLL
Number of subjects: 0
Study 34305947 — intervention group
Group type: COMPARATOR
Intervention: Comparative mass spectrometry-based immunopeptidome analyses of CLL samples
Number of subjects: 0
Study 34305948 — intervention group
Group type: EXPERIMENTAL
Intervention: GC5107 (10% intravenous immunoglobulin) administered at doses ranging from 319 to 881 mg/kg body weight every 21 or 28 days
Number of subjects: 49
Study 34305948 — intervention group
Group type: EXPERIMENTAL
Intervention: GC5107 (10% intravenous immunoglobulin)
Number of subjects: 49
Study 34306222 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous quitting (no smoking in the last 7 days and did not plan the quit in advance)
Number of subjects: 981